ClinicalTrials.gg
Not yet recruitingNCT07622810Updated Jun 3, 2026

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

A Phase 3 interventional study of Bofanglutida and Semaglutide in Obesity & Overweight, sponsored by Carnot Laboratories. Not yet recruiting at 6 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Carnot Laboratories · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Planned enrollment
3rd of 15
352 · median 140
Started
2026
with 3 others
Phase 3
5 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Carnot Laboratories

Among the 15 studies testing bofanglutide in Obesity, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 3, and was the 15th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and quality of life.

The main questions it aims to answer are:

Does Bofanglutide (GZR18) reduce body weight after 36 weeks of treatment compared with Semaglutide? What effects does Bofanglutide (GZR18) have on metabolic parameters, cardiovascular risk factors, and quality of life? How safe and well tolerated is treatment with Bofanglutide (GZR18)?

Researchers will compare Bofanglutide (GZR18) with Semaglutide, an active comparator, to evaluate efficacy and safety in adults with overweight or obesity.

Participants will:

Receive Bofanglutide (GZR18) every 2 weeks or Semaglutide once weekly by subcutaneous injection Follow standardized recommendations for diet and physical activity throughout the study Attend scheduled clinic visits for efficacy and safety assessments Participate in treatment and follow-up for up to 40 weeks, including screening, treatment, and safety follow-up periods

03

Conditions studied

  • Obesity & Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged ≥18 years.
  • (BMI): ≥30.0 kg/m² (obesity), or ≥27.0 kg/m² and \<30.0 kg/m² (overweight) with at least one weight-related comorbidity, including impaired glucose metabolism, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), osteoarthritis attributable to excess weight, or obstructive sleep apnea.
  • Body weight managed through diet and exercise alone for at least 12 weeks prior to screening, with \<5% change in body weight during the previous 12 weeks.
  • Willingness and ability to maintain a stable diet and physical activity regimen throughout the study.
  • Female participants of must not be pregnant or breastfeeding, must have a negative pregnancy test at screening and prior to randomization, and must agree to use a highly effective method of during the study and for at least 8 weeks after the last dose of study drug.
  • Male participants must agree to use effective contraception and refrain from sperm donation during the study and for at least 8 weeks after the last dose of study drug.
  • Ability to understand the study requirements and provide written prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to GLP-1 receptor agonists, GLP-1/GIP receptor agonists, or any component of the product.
  • History of substance abuse or alcoholism within 6 months prior to screening.
  • Presence of conditions that may interfere with accurate anthropometric assessments.
  • History of bariatric surgery or planned bariatric surgery during the study.
  • Obesity secondary to an underlying disease or medication.
  • Previous diagnosis of diabetes mellitus (except gestational diabetes).
  • History of severe hypoglycemia within 6 months prior to screening.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
  • History of within 5 years prior to screening, except adequately treated non-melanoma skin cancer or carcinoma in situ.
  • thyroid disease, pancreatitis, gallbladder disease, gastrointestinal disease, cardiovascular disease, cerebrovascular disease, hepatic disease, renal disease, or hematologic disease that, in the Investigator's judgment, may interfere with study participation.
  • Uncontrolled hypertension or clinically significant abnormalities.
  • Moderate or severe psychiatric disorders, clinically significant eating disorders, suicidal ideation or behavior, or a PHQ-9 score ≥15 at screening.
  • Clinically significant laboratory abnormalities at screening, including abnormalities in liver function, renal function, pancreatic enzymes, calcitonin, hematology, glycemic parameters, or positive testing for , active , , or syphilis.
  • Prior use of GLP-1 receptor agonists, dual/triple incretin agonists, weight-loss medications, hypoglycemic agents, or other medications that may affect body weight within 3 months prior to screening.
  • Acute infection requiring systemic treatment at screening or prior to randomization.
  • Participation in another interventional clinical trial within 90 days or 5 half-lives of the investigational product (whichever is longer) prior to randomization.
  • History of organ transplantation, major surgery, or severe trauma within 6 months prior to screening.
  • Any condition that, in the Investigator's judgment, may compromise participant safety, protocol compliance, or the validity of study results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (estimated)

Study arms

  • Experimental
    Group A: Bofanglutida (GZR18),

    Drug: Bofanglutida

  • Active comparator
    Group B: Semaglutide

    Drug: Semaglutide

Interventions

  • Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks. Participants will receive progressive dose titration starting at 3 mg up to a target dose of 48 mg according to the study protocol during the 36-week treatment period.

    Also known as: GZR18

  • Semaglutide is a GLP-1 receptor agonist administered by weekly subcutaneous injection with progressive dose titration from 0.25 mg to 1 mg according to the study protocol during the 36-week treatment period.

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight From Baseline to Week 36

    Evaluation of the percent change in body weight from baseline to Week 36 in participants receiving Bofanglutide (GZR18) compared with Semaglutide.

    Time frame: Baseline to Week 36

Secondary outcomes

  1. Proportion of Participants Achieving Clinically Relevant Weight Reduction

    Evaluation of the proportion of participants achieving clinically relevant body weight reductions of ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from baseline to Week 36.

    Time frame: Baseline to Week 36

  2. Change in Body Mass Index (BMI) From Baseline at Week 36

    Evaluation of the change in body mass index (BMI), expressed in kg/m², from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  3. Change in Hemoglobin A1c (HbA1c) From Baseline at Week 36

    Evaluation of the change in glycated hemoglobin (HbA1c), expressed as percentage (%), from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  4. Change in Fasting Plasma Glucose From Baseline at Week 36

    Evaluation of the change in fasting plasma glucose concentration from baseline to Week 36 during treatment

    Time frame: From Baseline at Week 36

  5. Change in Systolic Blood Pressure From Baseline at Week 36

    Evaluation of the change in systolic blood pressure from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  6. Change in Diastolic Blood Pressure From Baseline at Week 36

    Evaluation of the change in diastolic blood pressure from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  7. Change in Total Cholesterol From Baseline at Week 36

    Evaluation of the change in total cholesterol concentration from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  8. Change in Triglycerides From Baseline at Week 36

    Evaluation of the change in fasting triglyceride concentration from baseline to Week 36 during treatment

    Time frame: Baseline to Week 36

  9. Change in Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Total Score From Baseline at Week 36

    Evaluation of the change in the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) total score from baseline to Week 36 during treatment. Scores range from 0 to 100, with higher scores indicating better weight-related quality of life.

    Time frame: Baseline to Week 36

  10. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Evaluation of safety and tolerability based on adverse events, serious adverse events, laboratory assessments, and treatment discontinuations during the study.

    Time frame: From first dose through safety follow-up (up to 40 weeks)

  11. Change in Patient Health Questionnaire-9 (PHQ-9) Total Score From Baseline at Week 40

    Evaluation of the change in the Patient Health Questionnaire-9 (PHQ-9) total score from baseline to Week 40. The PHQ-9 is a self-administered questionnaire used to assess depressive symptoms. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: From first dose through safety follow-up (up to 40 weeks)

  12. Number of Participants With Suicidal Ideation or Behavior Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Evaluation of the occurrence of suicidal ideation or suicidal behavior during treatment with Bofanglutide (GZR18) compared with Semaglutide, assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: From first dose through safety follow-up (up to 40 weeks)

  13. Incidence of Anti-Drug Antibodies Against Bofanglutide

    Evaluation of the incidence of anti-drug antibodies (ADAs) against Bofanglutide during the study, including assessment of neutralizing antibodies (NAbs) and cross-reactivity with endogenous glucagon-like peptide-1 (GLP-1), as applicable.

    Time frame: From first dose through safety follow-up (up to 40 weeks)

  14. Early Assessment at Week 16

    Evaluation of the percent change in body weight from baseline and the proportion of participants achieving body weight reductions of ≥5% and ≥10% at Week 16.

    Time frame: Baseline to Week 16

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data collected during this study will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 15 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 3, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622810
Lead sponsor
Carnot Laboratories
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

Gisselle Vanessa González Hernández, Dr.
Contact
gvgonzalez@carnot.com
52
Emma Adriana Chávez Manzanera, Dr.
principal investigator · Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Clínica de Obesidad y Trastornos de la Conducta Alimentaria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion